Remove Bioavailability Remove Development Remove Drug Delivery Remove RNA
article thumbnail

Vevye: A New Cyclosporine Solution for Dry Eye Disease

XTalks

Sheppard, MD, MMSc, FACS, professor of ophthalmology at Eastern Virginia Medical School, and mid-atlantic medical director for Eye Care Partners and investigator in the development program. Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology.

article thumbnail

The Power of Lipids: Enhancing Drug Delivery with Nanoparticles

Roots Analysis

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cell-penetrating peptides as a delivery system for oligonucleotides

Drug Discovery World

Oligonucleotides act on the RNA level through different molecular pathways, but there is a major drawback when using them as drugs: their poor bioavailability and cellular uptake. When using a CPP as a delivery system, it must first be conjugated to its cargo molecule and internalised through endocytosis.

article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

CNS drugs treat a range of neurologic and psychiatric disorders, such as psychosis, depression, Parkinson’s disease, multiple sclerosis and epilepsy. Direct CNS administration techniques facilitate drug delivery to the brain to treat neurological disorders and these approaches are vital for CNS targets.

Trials 83